A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

Abstract Background Approximately 30–70% of patients who have undergone allogeneic (allo) hematopoietic stem cell transplantation (HSCT) eventually experience chronic graft-versus-host disease (cGVHD). Patients who develop steroid-refractory (SR)-cGVHD are the most severely impacted due to significa...

Full description

Bibliographic Details
Published in:Cost Effectiveness and Resource Allocation
Main Authors: Jian Chun Matthew Ong, Hein Than, Sandeep Tripathi, Christina Gkitzia, Xiaojun Wang
Format: Article
Language:English
Published: BMC 2023-05-01
Subjects:
Cost
cGVHD
Allogeneic
Transplant
Ruxolitinib
QALY
Online Access:https://doi.org/10.1186/s12962-023-00444-w

Internet

https://doi.org/10.1186/s12962-023-00444-w

Similar Items